A5018535039- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Cancer, Lipids, and Metabolism
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer, Hypoxia, and Metabolism
- Cancer Mechanisms and Therapy
- Lung Cancer Treatments and Mutations
- Liver Diseases and Immunity
- Renal cell carcinoma treatment
- Gastric Cancer Management and Outcomes
- Liver physiology and pathology
- HIV/AIDS drug development and treatment
- Diet, Metabolism, and Disease
- Systemic Lupus Erythematosus Research
- Gastrointestinal Tumor Research and Treatment
- Nutrition and Health in Aging
- Viral Infections and Immunology Research
- Lung Cancer Research Studies
- Organ Transplantation Techniques and Outcomes
- Fibroblast Growth Factor Research
Musashino Red Cross Hospital
2016-2025
Tokyo Medical and Dental University
2022-2023
Medical University of Vienna
2016-2022
The University of Tokyo
2019-2020
Kameda Medical Center
2020
University of Yamanashi
2013
Zero to Three
2013
Hokkaido University Hospital
2012
Weatherford College
2007
Kitasato University
1998
An increase in the aging population is an impending problem. A large cohort study was carried out to determine influence of and other factors on hepatocarcinogenesis patients treated with interferon. Biopsy-proven 2547 chronic hepatitis C registered at our referral center since 1992 were included. Of these, 2166 interferon-based therapy. Incidences hepatocellular carcinoma (HCC) associated interferon analyzed by Kaplan-Meier person-years methods for average follow-up 7.5 years. Factors HCC...
The effects of interferon (IFN) treatment and the post-IFN α-fetoprotein (AFP) levels on risk hepatocellular carcinoma (HCC) in patients with chronic hepatitis C (CHC) are unknown. To determine relationship between AFP alanine transaminase (ALT) HCC risk, a cohort consisting 1,818 histologically proven to have CHC treated IFN were studied. Cumulative incidence analyzed over mean follow-up period 6.1 years using Kaplan-Meier method Cox proportional hazard analysis. developed 179 study...
The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by Japan Society Hepatology, according to methodology evidence-based medicine and partly Grading Recommendations Assessment, Development Evaluation system, which published in October 2021 Japanese. In addition surveillance-diagnostic treatment algorithms, a new algorithm systemic therapy has been created, as multiple drugs hepatocellular carcinoma can be currently selected. Here, or algorithms...
Atezolizumab plus bevacizumab therapy is extremely effective in the treatment of intermediate-stage hepatocellular carcinoma (HCC), with a response rate 44%, as reported IMbrave150 trial. When tumor shrinkage obtained, achieving complete (CR) possible many cases using curative conversion resection, ablation, or superselective transarterial chemoembolization (TACE) intent. This concept, i.e., by combining systemic and locoregional therapy, has not been before. multicenter proof-of-concept...
The response rate to sorafenib in hepatocellular carcinoma (HCC) is relatively low (0.7%-3%), however, rapid and drastic tumor regression occasionally observed. molecular backgrounds clinico-pathological features of these responders remain largely unclear. We analyzed the clinical 13 with significant shrinkage a retrospective study. A comparative genomic hybridization analysis using one frozen HCC sample from responder demonstrated that 11q13 region, rare amplicon including loci for FGF3...
Magnetic resonance elastography (MRE) has the highest diagnostic accuracy for liver fibrosis; however, association between MRE-associated stiffness and development of hepatic extrahepatic complications as well mortality remains unclear.In this study, we investigated longitudinal mortality.This retrospective study included 2373 consecutive patients with chronic disease. All received standard care was assessed every 1-6 months.Newly diagnosed hepatocellular carcinoma (HCC), decompensation,...
<b><i>Introduction:</i></b> Hepatic arterial infusion chemotherapy (HAIC) with cisplatin and lenvatinib exhibits strong antitumor effects against advanced hepatocellular carcinoma (HCC). Higher activity is expected for the combination treatment. The aim of this trial was to evaluate efficacy safety in HAIC using patients HCC. <b><i>Methods:</i></b> In multicenter, open-labeled, single-arm, phase II trial, HCC categorized as Child-Pugh class A...
A multisociety consensus group proposed a new nomenclature for metabolic dysfunction-associated steatotic liver disease (MASLD). Although patients with nonalcoholic fatty (NAFLD) are expected to be reclassified as MASLD under the nomenclature, concordance between and NAFLD remains unclear. Moreover, waist circumference could adjusted by ethnicity diagnosing MASLD; however, there limited data on optimal in Japanese population.
Abstract Aims Optimizing glycemic control may prevent liver‐related events and major adverse cardiovascular (MACE) in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). However, the optimal hemoglobin A1c (HbA1c) threshold associated a lower risk of complications, particularly as well MACE is unknown. Methods We investigated nationwide population‐based cohort identified 633 279 MASLD, mean follow‐up 4.2 years. Hemoglobin levels were measured annually. The primary...
Abstract Aim We aimed to evaluate the effect of pemafibrate, a selective peroxisome proliferator‐activated receptor‐α modulator, on patients with primary biliary cholangitis (PBC) complicated by dyslipidemia. Methods In total, 61 PBC (Add‐on group: 33 ursodeoxycholic acid [UDCA] + pemafibrate combination therapy; Switch 28 who switched from UDCA other fibrates therapy) were included in study. Changes aspartate aminotransferase (AST), alanine (ALT), gamma‐glutamyl transferase (GGT), alkaline...
Abstract Background Atezolizumab plus bevacizumab is recommended as a first-line treatment for unresectable hepatocellular carcinoma (uHCC). A subgroup analysis of the IMbrave150 trial showed shorter overall survival (OS) in uHCC patients with stable disease (SD) than complete response (CR) or partial (PR) after atezolizumab bevacizumab. Improving OS SD an unmet medical need. Transcatheter arterial chemoembolization (TACE) may enhance efficacy by controlling intrahepatic lesions and...
<i>Objectives:</i> The aim of this study was to investigate the relationships between early changes in tumor markers α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP), antitumor response period following administration sorafenib patients with advanced hepatocellular carcinoma (HCC). <i>Methods:</i> Forty-eight HCC were evaluated. AFP DCP measured at baseline, after 2 4 weeks, responses evaluated according RECIST criteria weeks starting therapy. ratios each...
Aim Intermediate‐stage hepatocellular carcinoma varies widely in tumor burden and liver function. This study aimed to clarify the importance of subclassification by up‐to‐seven criteria both clinical course function deterioration such patients. Methods We retrospectively analyzed 224 patients with Child–Pugh grade A who underwent initial transarterial chemoembolization (TACE) for carcinoma. Tumor downstaging within Milan 1 year worsening as from B were analyzed. Results The median survival...
The present study aimed to investigate the impact of pre-sarcopenia on prognosis patients with advanced hepatocellular carcinoma (HCC) treated sorafenib.We enrolled 214 (71 ± 10 years old; 166 men and 48 women; 90% Child-Pugh grade A 10% B) sorafenib in our hospital from July 2009 August 2016. muscle volume was measured CT images just before administration using software (SliceOmatic). Skeletal mass index calculated, presence judged according standard (42 cm2/m2 for 38 women) proposed by...
Lenvatinib is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), but the effect of dose modification on its efficacy unclear. We analyzed relationship between relative intensity during initial 4 weeks [4W-relative (RDI)] and lenvatinib in real-world setting. A total 48 consecutive patients with HCC who received more than were included. The 4W-RDI was calculated as cumulative divided by weight-based standard dose, we evaluated association overall survival (OS)...
The association between liver fibrosis, fatty liver, and cardiovascular disease (CVD) risk is unknown. Hence, this study aimed to investigate the of fibrosis with CVD independent already known comorbidities.This a prospective registered University Hospital Medical Information Network clinical trial registry (UMIN000036175). Liver was assessed by serum markers including FIB-4, nonalcoholic score (NFS), Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+ -M2BP), whereas...
Background: Lenvatinib (LEN) has been approved for patients with unresectable hepatocellular carcinoma (u-HCC) since March 2018 in Japan. We performed a retrospective nationwide multicenter study to clarify the clinical characteristics of LEN real-world practice. Methods: A total 343 u-HCC who received from May 2020 at 23 sites Japan were registered. Results: During median observation period 10.5 months, 143 died. In Child-Pugh (n = 276) and B 67) patients, overall survival (OS) was 21.0 9.0...
We investigated pretreatment neutrophil-to-lymphocyte ratio (NLR) for predicting survival outcomes of atezolizumab plus bevacizumab therapy hepatocellular carcinoma (HCC) and determined the predictive ability combined liver reserve-NLR.This retrospective, multicenter study enrolled 242 patients receiving unresectable HCC. Pretreatment NLR <2.56 was designated as "low group" ≥2.56 "high (120 122 patients, respectively). Propensity score-matched analysis undertaken between low high groups.In...
The phase III IMbrave150 study established atezolizumab + bevacizumab as standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis reports efficacy and safety results baseline Barcelona Clinic Liver Cancer (BCLC) stage B disease.Patients systemic treatment-naive HCC Child-Pugh class A liver function were randomized 2:1 to receive 1,200 mg plus 15 mg/kg or 400 sorafenib. Co-primary endpoints overall survival (OS) progression-free (PFS) per...
Non-alcoholic steatohepatitis (NASH) is one of the representative liver diseases in developed countries. Diagnosis NASH dependent on histological findings from biopsy.The usefulness contrast ultrasound with Levovist for diagnosis described. 2.5 g agent was injected intravenously. The scanned at 5, 10, 15, 20, 30, 40 and 50 min changes microbubble accumulation were evaluated. signal intensity regions interest (ROI) images measured estimated using time curves (TICs). Twenty-one patients NASH,...
<i>Objective:</i> Keratin (K) 19 positivity has been reported to be a useful predictive marker for recurrence in patients with hepatocellular carcinoma (HCC) who have undergone hepatic resection. We investigated the clinical usefulness of K19 had received curative radiofrequency ablation (RFA). <i>Methods:</i> retrospectively evaluated clinicopathological features, including imaging and expression, 246 HCC were within Milan criteria RFA. Using two-step insertion...